header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

Hip

WHEN ARE PATIENTS MOST VULNERABLE TO A REVISION TOTAL HIP ARTHROPLASTY? A RETROSPECTIVE STUDY USING HOSPITAL AND NATIONAL JOINT REGISTRY DATA

The British Hip Society (BHS) Meeting, Nottingham, England, 27 February – 1 March 2019.



Abstract

Patients need to know the benefits, risks and alternatives to any proposed treatment. Surgeons discussing the risk of a revision procedure becoming necessary, after a hip replacement can draw upon the orthopaedic literature and arthroplasty registries for long-term implant survival. However, early revision is required in a minority of cases. We have investigated the probability for revision hip replacement patients in terms of time-point and indication for revision.

Of the 9,411 Primary Total Hip Replacements (THR), undertaken by 22 surgeons, over an eleven-year period, between January 2004 and March 2015, 1.70% (160) were subsequently reported to the National Joint Registry (NJR) as revised. Each revision case was reviewed under the supervision of senior hip specialist consultants. The modes of failure of were identified through clinical, laboratory and imaging (x-rays, CT, MRI and Isotope scans) studies.

The revision rate for THRs was 0.58% in the first year. This was statistically higher than all subsequent years, P-Value <0.001. There was no statistical difference between any pair of subsequent years. Thereafter, the average revision rate was 0.30% per annum. The odds ratio for revision during the first post–operative year against the subsequent year average was 1.67.

The indications for the early hip revisions in the first three years were infection, dislocation and peri-prosthetic fracture. The data from this study can help better inform patients of the revision rates after a primary THR and allow surgeons to develop implant surveillance strategies among high-risk patients.


Email: